Últimas noticias sobre XIAO-I (NASDAQ:AIXI) Bolsa

XIAO-I

XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.

XIAO-I Corporation - American Depositary Shares

XIAO-I Corp

AIXIN LIFE INTL INC by AiXin Life International, Inc.

AiXin Life International Inc

Aixia Group AB

Main Street's preliminary estimate of net asset value ("NAV") per share as of June&nbsp;30, 2025 is $32.27 to $32.33, representing an increase of $0.24 to $0.30 per share, or 0.7% to 0.9%, from the NAV per share of $32.03 as of March 31, 2025, with this increase after the impact of the supplemental dividend paid in June 2025 of $0.30 per share. The estimated increase in NAV per share is primarily due to the net fair value increase on the investment portfolio and the accretive impact of equity issuances, partially offset by a decrease due to the issuance of restricted stock. The net fair value increase on the investment portfolio is the result of net fair value increases on the wholly-owned asset manager and the lower middle market ("LMM") investment portfolio, partially offset by net fair value decreases on the private loan and middle market investment portfolios.

News

MAIN

Main Street's Preliminary Estimate Of NAV Per Share As Of June 30, 2025 Is $32.27 - $32.33, Up 0.7% - 0.9%, From NAV Per Share Of $32.03 As Of March 31, 2025

IMAB

I-Mab Acquires Bridge Health To Secure Full IP Rights For Givastomig, Eliminate Royalties, And Accelerate Development Of CLDN18.2 Cancer Therapy

CLSD

Clearside Says Alternatives Under Consideration Include Sale, License, Monetization And/Or Divestitures

&nbsp;<a href="https://recurrentenergy.com/">Recurrent Energy</a>, a subsidiary of <a href="https://www.canadiansolar.com/">Canadian Solar Inc.</a>&nbsp;("Canadian Solar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) and a global developer, owner, and operator of solar and energy storage assets, announced today it has closed project financing and tax equity for Blue Moon Solar. U.S. Bank, through its subsidiary U.S. Bancorp Impact Finance, is providing both tax equity and construction financing for the project, totaling $260 million.
Constellation will purchase power and renewable energy certificates produced by the 94 MW energy facility under a power purchase agreement with Recurrent Energy. Located in Harrison County, Kentucky, Blue Moon Solar is currently under construction and expected to reach commercial operation in 2026. Recurrent Energy will own and operate the project after it is energized.

CSIQ

Canadian Solar Subsidiary Recurrent Energy Secures $260M to Build Solar Power Plant in Kentucky

B of A Securities analyst Ebrahim Poonawala maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Buy and raises the price target from $26 to $27.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on First Horizon, Raises Price Target to $27

FFIV

F5 And MinIO Expand Partnership To Deliver High-Performance, Secure AI Data Pipelines For Edge-To-Factory Workloads Across Industries

Clearside Biomedical  To Explore Full Range Of Strategic Alternatives To Advance Its Suprachoroidal Delivery Platform

Preliminary Estimates of Second Quarter 2025 Results
Main Street's preliminary estimate of second quarter 2025 net investment income ("NII") is $0.98 to $1.00 per share and distributable net investment income ("DNII") is $1.05 to $1.07 per share.(1) The preliminary estimates of NII and DNII include $0.05 to $0.06 per share of NII related federal and state income, excise and other tax expenses.

Main Street Capital Preliminary Estimate Of Q2 Net Investment Income Is $0.98 - $1.00 Per Share And Distributable Net Investment Income Is $1.05 - $1.07 Per Share

BMO Capital analyst Ameet Thakkar downgrades Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) from Outperform to Market Perform and raises the price target from $352 to $400.

Downgrades

BMO Capital Downgrades Quanta Services to Market Perform, Raises Price Target to $400

WIIM

RCKT

Rocket Pharmaceuticals shares are trading higher after the company received FDA Regenerative Medicine Advanced Therapy designation for RP-A601 gene therapy in PKP2-arrhythmogenic cardiomyopathy.

RBLX

Roblox Introduces Suite Of Safety Tools Giving Teens More Control And Parents Greater Transparency

Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ&#xAE; (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ&#x2122; (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases.
BYOOVIZ has been commercialized by Biogen in the U.S. since its initial launch in June 2022. In October 2024, Biogen notified Samsung Bioepis of their decision to terminate the 2019 Development and Commercialization Agreement within the U.S. and Canada. Samsung Bioepis has been closely working with Biogen on the transfer of commercialization rights for BYOOVIZ and OPUVIZ back to Samsung Bioepis in these regions. Harrow will assume full responsibility for commercialization of BYOOVIZ in the U.S. upon completion of the transition of commercial rights from Biogen back to Samsung Bioepis. The transition is expected to be completed by the end of 2025.
This strategic acquisition enhances Harrow's position as the leading full-spectrum ophthalmic pharmaceuticals provider in the U.S., expands its pipeline with high-value biosimilars for sight‑threatening retinal diseases, and reinforces its commitment to delivering value-oriented innovation to the U.S. eyecare market.

HROW

SSNLF

Harrow Secures US Rights to Two Vision-Saving Eye Drug Alternatives From Samsung

Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has introduced a new platform aimed at revolutionizing the workplace with AI technology.
What Happened: Amazon Web Services (AWS) on Wednesday unveiled the Amazon Bedrock AgentCore, a customizable service that allows businesses to create a network of interconnected AI agents. These agents can perform tasks such as data analysis and coding, freeing up human employees to focus on more creative and strategic work, <a href="https://www.semafor.com/article/07/16/2025/amazon-launches-ai-agent-building-platform-for-businesses-to-help-boost-productivity">reported</a> Semafor.
The platform was introduced by Swami Sivasubramanian, the company&#8217;s vice president of agentic AI, at the AWS Summit in New York.
The AI agents can operate in the background for up to eight hours and are compatible with popular MCP and A2A protocols, enabling communication with other agents outside the company.
Deepak Singh, vice president of developer agents and experiences, described AgentCore as a significant step towards the widespread adoption of agentic AI, likening its potential to that of the internet.
See Also: <a href="https://benzinga.com/markets/tech/25/07/46438576/nvidia-is-on-a-march-to-5-trillion-market-capitalization-says-dan-ives-as-he-predicts-bullish-environment-for-tech-and-crypto-very-strong-second-half" target="_blank" rel="noopener">Nvidia Is &#8216;On A March To $5 Trillion&#8217; Market Capitalization, Says Dan Ives As He Predicts Bullish Environment For Tech And Crypto: &#8216;Very Strong Second Half&#8217;</a>
Amazon&#8217;s announcement comes on the heels of similar product launches from rivals like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, and OpenAI. However, AWS sets itself apart by offering agents that are compatible with any framework or model, not just those within the Bedrock ecosystem.
At the New York event, Amazon also introduced a dashboard for employers to monitor agent performance and a marketplace for developers to buy and sell agents.
Why It Matters: Amazon&#8217;s new platform is the latest in a series of moves by the company to solidify its position in the AI space.
In June, Amazon launched a new team within its consumer R&amp;D division to focus on <a href="https://www.benzinga.com/markets/tech/25/06/45783322/amazon-launches-new-agentic-ai-group-to-boost-robotics-enhance-user-interactions">agentic artificial intelligence</a>. In July, the company unveiled <a href="https://www.benzinga.com/markets/tech/25/07/46342110/amazon-unveils-powerful-new-ai-servers-to-support-nvidias-most-advanced-chips">powerful new AI servers</a> to support Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) most advanced chips.
Amazon&#8217;s commitment to AI is further evidenced by its potential <a href="https://www.benzinga.com/markets/tech/25/07/46336890/amazon-may-pour-billions-more-into-anthropic-as-13-8-billion-ai-bet-grows-report">multibillion-dollar investment</a> in Anthropic, a San Francisco-based AI model builder. The company is reportedly considering an additional investment to extend its existing $8 billion commitment.
Price Action: Amazon ended Wednesday at $223.19, down 1.40% and gained slightly to $223.95 in pre-market trading, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/07/46452042/xrp-surges-25-in-1-week-heres-when-it-will-hit-a-new-all-time-high" target="_blank" rel="noopener">XRP Surges 25% In 1 Week: Here&#8217;s When It Will Hit A New All-Time High</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

AMZN

GOOG

GOOGL

MSFT

NVDA

Amazon's Bedrock AgentCore Platform Hints At Future Of Work: AI Agents That Think, Code And Collaborate

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation For RP-A601 Gene Therapy In PKP2-Arrhythmogenic Cardiomyopathy

BMO Capital analyst Raj Ray initiates coverage on Harmony Gold Mining Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) with a Market Perform rating and announces Price Target of $16.

Initiation

BMO Capital Initiates Coverage On Harmony Gold Mining Co with Market Perform Rating, Announces Price Target of $16

SelectQuote, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced the expanded launch of their innovative concierge-like service designed to specifically improve medication adherence for Medicare beneficiaries managing multiple chronic conditions and complex medication regimens. SelectQuote's SelectRx pharmacy recently trialed a new approach with a regional health plan that demonstrated over 90% adherence, strengthening HEDIS Star ratings across the triple-weighted cholesterol, diabetes and hypertension measures. The Company plans to expand to additional payers this calendar year and will roll out across SelectRx's pharmacy platform in 2026.
 &nbsp;

SLQT

SelectQuote Launches Concierge-Like Service To Improve Medication Adherence For Medicare Beneficiaries Managing Multiple Chronic Conditions And Complex Medication Regimens

General

MOBX

Mobix Labs Says Its EMI Filter Solutions Subsidiary Saw Sharp Uptick In Production Orders In Q2

Baird analyst Ghansham Panjabi downgrades Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) from Outperform to Neutral and announces $105 price target.

Baird Downgrades Crown Holdings to Neutral, Announces $105 Price Target

HBIO

Harvard Bioscience Appoints John Duke As CEO, Adds Two Independent Directors, Reaffirms Q2 Revenue Outlook Of $20.4M And Margin Guidance

<a href="http://www.nlspharma.com/">NLS Pharmaceutics Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S. Binational Industrial Research and Development Foundation (the "Bird Foundation") has approved another milestone-based funding payment to <a href="file:///C:/Users/ngil/Downloads/kadimastem.com">Kadimastem Ltd</a>. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing "off-the-shelf," allogeneic regenerative treatments for neurodegenerative diseases and diabetes, with a U.S.-based company, iTolerance, Inc. ("iTolerance"). The milestone payment is based on the significant progress demonstrated by the companies in the co-development of iTOL-102, a novel cell therapy targeting a potential cure for Type 1 diabetes without the need for life-long immunosuppression.
&nbsp;
This news follows the February 2025 announcement by NLS and Kadimastem regarding the successful completion of a Type B Pre-IND meeting with the U.S. Food and Drug Administration (the "FDA"). The FDA provided constructive guidance on the clinical development pathway, enabling the companies to advance toward initiating First-in-Human clinical trials of iTOL-102. The BIRD Foundation's approval of a fifth disbursement of funds is based on the program's recent scientific and regulatory progress.
The milestone payment approved by the BIRD Foundation amounts to approximately NIS 564,400 ($166,000 USD), bringing the total support from the BIRD Foundation to nearly NIS 3 million ($882,352 USD) to date. NLS and Kadimastem believe that the continued financial backing reflects the BIRD Foundation's ongoing confidence in the collaboration between Kadimastem and iTolerance and the clinical promise of iTOL-102.

NLSP

NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation

Press Releases

Technical Innovation Is at Heart of Global Explosion of Smart Glasses Markets as Demand Jumps

Xiao-I (AIXI) Responds to "DeepSeek" Developments, Showcases Cost-Effective RL Breakthroughs in Hua Zang LLM, and Announces U.S. Expansion

Xiao-I Corporation Delivers Transformative AI-Powered HR Solution to Hong Kong Public Sector, Showcasing Scalable MaaS Excellence

Xiao-I Corporation Unveils tAIkbox 1: Turning Frustrating Automated Calls into Exceptional Customer Service

Fintech

Xiao-I Corporation Announces Strategic Partnership with TF International to Advance AI-Powered Financial Services

Xiao‑I Corporation Crosses into Profitability on Run‑Rate Basis; Pre‑Announces 2024 Revenue Up 19% and Guides to Full‑Year Profit in 2025

Small Cap

Xiao-I Corporation Advances AI Glasses Commercialization with Sales Surpass 1,500 Units; Reaffirms $12-15M Business Unit Revenue Target for 2025

Xiao-I Launches AI Golf Booking Platform, Signaling Expansion into Broader Sports and Facility Management

Insurance

Xiao-I Corporation Expands Strategic Partnership with AIA China Through RMB 3-4 Million AI Solutions Deal

Earnings

Xiao-I Corporation Announces Strong 2024 Results: Revenue Up 19% with Path to Profitability in 2025

Comments

XIAO-I

Noticias

Últimas noticias sobre XIAO-I (NASDAQ:AIXI) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL